On the other hand, much of the value of priority review vouchers will depend on how the FDA evaluates those drugs that previously would not have been eligible for such review. Drug developers are ...

Spark Therapeutics has sold a priority review voucher, entitling the holder to a faster six-month FDA drug review, to Ireland’s Jazz Pharmaceuticals for $110m, a fraction of the price these ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV ... contractually defined percentage of the PRV value,” said the Dutch biotech in a statement issued this ...

Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first ...

These protections allow innovator products to command higher prices than generics. Therefore, the market value of generic priority review vouchers is likely to be lower than that of innovator products ...

30, 2026, to receive vouchers for their qualifying drugs, after that, the FDA will no longer be allowed to give out priority review vouchers.

As described below, Cyprium is eligible to receive royalties and retains ownership of any Priority Review Voucher that may be ... assets to enhance long-term value for shareholders through product ...

The VERV program is modeled after the successful Tropical Disease Priority Review Voucher Program that was ... Speeding a second product to market generates value for the manufacturer, which ...